The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (ADJUNCT ONE™)

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial

This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.

Study Overview

• Status: Completed
• Conditions: Diabetes; Diabetes Mellitus, Type 1
• Intervention / Treatment: Drug: liraglutide; Drug: placebo

• Study Type: Interventional
• Enrollment (Actual): 1398
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Caba, Argentina, C1440AAD
    • Novo Nordisk Investigational Site
  • Caba, Argentina, C1118AAT
    • Novo Nordisk Investigational Site
  • Capital Federal, Argentina, 1405
    • Novo Nordisk Investigational Site
  • Córdoba, Argentina, X5016KEH
    • Novo Nordisk Investigational Site
  • Mendoza, Argentina, 5500
    • Novo Nordisk Investigational Site
  • Morón, Argentina, B1708IFF
    • Novo Nordisk Investigational Site
• Australia
  • New South Wales
    • Broadmeadow, New South Wales, Australia, 2292
      • Novo Nordisk Investigational Site
  • South Australia
    • Elizabeth Vale, South Australia, Australia, 5112
      • Novo Nordisk Investigational Site
    • Keswick, South Australia, Australia, 5035
      • Novo Nordisk Investigational Site
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Novo Nordisk Investigational Site
    • Parkville, Victoria, Australia, 3050
      • Novo Nordisk Investigational Site
• Belgium
  • Arlon, Belgium, 6700
    • Novo Nordisk Investigational Site
  • Edegem, Belgium, 2650
    • Novo Nordisk Investigational Site
  • Leuven, Belgium, 3000
    • Novo Nordisk Investigational Site
  • Liège, Belgium, 4000
    • Novo Nordisk Investigational Site
• Canada
  • Quebec, Canada, G1V 4G2
    • Novo Nordisk Investigational Site
  • Quebec, Canada, G1V 4G5
    • Novo Nordisk Investigational Site
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2E1
      • Novo Nordisk Investigational Site
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3E 3P4
      • Novo Nordisk Investigational Site
  • Ontario
    • Barrie, Ontario, Canada, L4M 7G1
      • Novo Nordisk Investigational Site
    • Cambridge, Ontario, Canada, N1R 7L6
      • Novo Nordisk Investigational Site
    • London, Ontario, Canada, N6A 4V2
      • Novo Nordisk Investigational Site
    • Mississauga, Ontario, Canada, L5M 2V8
      • Novo Nordisk Investigational Site
    • Oakville, Ontario, Canada, L6M 1M1
      • Novo Nordisk Investigational Site
    • Thornhill, Ontario, Canada, L4J 8L7
      • Novo Nordisk Investigational Site
    • Toronto, Ontario, Canada, M4G 3E8
      • Novo Nordisk Investigational Site
    • Toronto, Ontario, Canada, M5C 2T2
      • Novo Nordisk Investigational Site
    • Toronto, Ontario, Canada, M5T 3L9
      • Novo Nordisk Investigational Site
  • Quebec
    • Montreal, Quebec, Canada, H2W 1R7
      • Novo Nordisk Investigational Site
    • Sherbrooke, Quebec, Canada, J1G 5K2
      • Novo Nordisk Investigational Site
• Finland
  • Helsinki, Finland, 00250
    • Novo Nordisk Investigational Site
  • Helsinki, Finland, 00029
    • Novo Nordisk Investigational Site
  • Pori, Finland, 28500
    • Novo Nordisk Investigational Site
  • Seinäjoki, Finland, 60220
    • Novo Nordisk Investigational Site
  • Seinäjoki, Finland, 60510
    • Novo Nordisk Investigational Site
  • Tampere, Finland, 33520
    • Novo Nordisk Investigational Site
  • Turku, Finland, FI-20520
    • Novo Nordisk Investigational Site
• France
  • Besancon, France, 25030
    • Novo Nordisk Investigational Site
  • Brest, France, 29609
    • Novo Nordisk Investigational Site
  • Caen, France, 14033
    • Novo Nordisk Investigational Site
  • Corbeil Essonnes, France, 91106
    • Novo Nordisk Investigational Site
  • DIJON cedex, France, 21079
    • Novo Nordisk Investigational Site
  • Le Creusot, France, 71200
    • Novo Nordisk Investigational Site
  • Narbonne, France, 11108
    • Novo Nordisk Investigational Site
  • Paris, France, 75877
    • Novo Nordisk Investigational Site
  • Pointe à Pitre, France, 97159
    • Novo Nordisk Investigational Site
  • Poitiers, France, 86000
    • Novo Nordisk Investigational Site
  • Saint Herblain, France, 44800
    • Novo Nordisk Investigational Site
  • Saint Priest en Jarez, France, 42270
    • Novo Nordisk Investigational Site
  • Venissieux, France, 69200
    • Novo Nordisk Investigational Site
• Germany
  • Eisenach, Germany, 99817
    • Novo Nordisk Investigational Site
  • Essen, Germany, 45219
    • Novo Nordisk Investigational Site
  • Hamburg, Germany, 22607
    • Novo Nordisk Investigational Site
  • Hamburg, Germany, 21073
    • Novo Nordisk Investigational Site
  • Hohenmölsen, Germany, 06679
    • Novo Nordisk Investigational Site
  • Marburg, Germany, 35039
    • Novo Nordisk Investigational Site
  • Münster, Germany, 48145
    • Novo Nordisk Investigational Site
  • Pohlheim, Germany, 35415
    • Novo Nordisk Investigational Site
  • Rehlingen-Siersburg, Germany, 66780
    • Novo Nordisk Investigational Site
  • St. Ingbert, Germany, 66386
    • Novo Nordisk Investigational Site
• Ireland
  • Dublin, Ireland, DUBLIN 15
    • Novo Nordisk Investigational Site
  • Dublin, Ireland, DUBLIN 4
    • Novo Nordisk Investigational Site
  • Dublin, Ireland, DUBLIN 7
    • Novo Nordisk Investigational Site
  • Dublin 9, Ireland
    • Novo Nordisk Investigational Site
  • Galway, Ireland
    • Novo Nordisk Investigational Site
• Israel
  • Haifa, Israel, 31096
    • Novo Nordisk Investigational Site
  • Holon, Israel, 58100
    • Novo Nordisk Investigational Site
  • Jerusalem, Israel, 91120
    • Novo Nordisk Investigational Site
  • Jerusalem, Israel, 93106
    • Novo Nordisk Investigational Site
  • Petah Tikva, Israel, 49202
    • Novo Nordisk Investigational Site
  • Rishon Le Zion, Israel, 75650
    • Novo Nordisk Investigational Site
• Netherlands
  • Amsterdam, Netherlands, 1105 AZ
    • Novo Nordisk Investigational Site
  • Den Haag, Netherlands, 2512 VA
    • Novo Nordisk Investigational Site
  • Hoogeveen, Netherlands, 7909 AA
    • Novo Nordisk Investigational Site
  • Leiden, Netherlands, 2333 ZA
    • Novo Nordisk Investigational Site
  • Nijmegen, Netherlands, 6525 GA
    • Novo Nordisk Investigational Site
  • Rotterdam, Netherlands, 3011 TA
    • Novo Nordisk Investigational Site
  • Venlo, Netherlands, 5912 BL
    • Novo Nordisk Investigational Site
• Norway
  • Bergen, Norway, 5021
    • Novo Nordisk Investigational Site
  • Gjettum, Norway, 1346
    • Novo Nordisk Investigational Site
  • Hamar, Norway, 2318
    • Novo Nordisk Investigational Site
  • Kongsvinger, Norway, 2226
    • Novo Nordisk Investigational Site
  • Stavanger, Norway, 4011
    • Novo Nordisk Investigational Site
• Poland
  • Lublin, Poland, 20-044
    • Novo Nordisk Investigational Site
  • Pulawy, Poland, 24-100
    • Novo Nordisk Investigational Site
  • Warszawa, Poland, 00-911
    • Novo Nordisk Investigational Site
  • Warszawa, Poland, 03-242
    • Novo Nordisk Investigational Site
  • Zabrze, Poland, 41-800
    • Novo Nordisk Investigational Site
• Russian Federation
  • Kazan, Russian Federation, 420012
    • Novo Nordisk Investigational Site
  • Kazan, Russian Federation, 420073
    • Novo Nordisk Investigational Site
  • Penza, Russian Federation, 440026
    • Novo Nordisk Investigational Site
  • Saratov, Russian Federation, 410012
    • Novo Nordisk Investigational Site
  • Volgograd, Russian Federation, 400138
    • Novo Nordisk Investigational Site
• Sweden
  • Göteborg, Sweden, 413 45
    • Novo Nordisk Investigational Site
  • Malmö, Sweden, 205 02
    • Novo Nordisk Investigational Site
  • Stockholm, Sweden, 141 86
    • Novo Nordisk Investigational Site
  • Stockholm, Sweden, 112 81
    • Novo Nordisk Investigational Site
• Ukraine
  • Kharkov, Ukraine, 61058
    • Novo Nordisk Investigational Site
  • Kharkov, Ukraine, 61070
    • Novo Nordisk Investigational Site
  • Kiev, Ukraine, 04114
    • Novo Nordisk Investigational Site
  • Poltava, Ukraine, 36011
    • Novo Nordisk Investigational Site
  • Zhytomir, Ukraine, 10002
    • Novo Nordisk Investigational Site
• United Kingdom
  • Blackburn, United Kingdom, BB2 3HH
    • Novo Nordisk Investigational Site
  • Bristol, United Kingdom, BS10 5NB
    • Novo Nordisk Investigational Site
  • Durham, United Kingdom, DH11 5TW
    • Novo Nordisk Investigational Site
  • Edgbaston, Birmingham, United Kingdom, B15 2TH
    • Novo Nordisk Investigational Site
  • Edinburgh, United Kingdom, EH4 2XU
    • Novo Nordisk Investigational Site
  • Middlesbrough, United Kingdom, TS4 3BW
    • Novo Nordisk Investigational Site
  • Plymouth, United Kingdom, PL6 8BQ
    • Novo Nordisk Investigational Site
  • Southall, United Kingdom, UB1 3HW
    • Novo Nordisk Investigational Site
  • St Helens, United Kingdom, WA9 3DA
    • Novo Nordisk Investigational Site
  • Stevenage, United Kingdom, SG1 4AB
    • Novo Nordisk Investigational Site
• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Novo Nordisk Investigational Site
  • California
    • Concord, California, United States, 94520
      • Novo Nordisk Investigational Site
    • Encino, California, United States, 91436
      • Novo Nordisk Investigational Site
    • Escondido, California, United States, 92025
      • Novo Nordisk Investigational Site
    • Huntington Beach, California, United States, 92648
      • Novo Nordisk Investigational Site
    • La Mesa, California, United States, 91942
      • Novo Nordisk Investigational Site
    • Lancaster, California, United States, 93534
      • Novo Nordisk Investigational Site
    • Monterey, California, United States, 93940
      • Novo Nordisk Investigational Site
    • San Mateo, California, United States, 94401
      • Novo Nordisk Investigational Site
    • San Ramon, California, United States, 94583
      • Novo Nordisk Investigational Site
    • Walnut Creek, California, United States, 94598
      • Novo Nordisk Investigational Site
  • Colorado
    • Denver, Colorado, United States, 80209
      • Novo Nordisk Investigational Site
  • Florida
    • Ft. Lauderdale, Florida, United States, 33312
      • Novo Nordisk Investigational Site
    • Hialeah, Florida, United States, 33012
      • Novo Nordisk Investigational Site
    • Jacksonville, Florida, United States, 32258
      • Novo Nordisk Investigational Site
    • Tampa, Florida, United States, 33619
      • Novo Nordisk Investigational Site
  • Georgia
    • Atlanta, Georgia, United States, 30318
      • Novo Nordisk Investigational Site
    • Atlanta, Georgia, United States, 30308-2253
      • Novo Nordisk Investigational Site
    • Marietta, Georgia, United States, 30060
      • Novo Nordisk Investigational Site
    • Roswell, Georgia, United States, 30076
      • Novo Nordisk Investigational Site
    • Savannah, Georgia, United States, 31405
      • Novo Nordisk Investigational Site
  • Idaho
    • Idaho Falls, Idaho, United States, 83404-7596
      • Novo Nordisk Investigational Site
  • Indiana
    • Indianapolis, Indiana, United States, 46254
      • Novo Nordisk Investigational Site
  • Iowa
    • Council Bluffs, Iowa, United States, 51501
      • Novo Nordisk Investigational Site
    • Iowa City, Iowa, United States, 52242
      • Novo Nordisk Investigational Site
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Novo Nordisk Investigational Site
  • Louisiana
    • Metarie, Louisiana, United States, 70006
      • Novo Nordisk Investigational Site
  • Maryland
    • Baltimore, Maryland, United States, 21229
      • Novo Nordisk Investigational Site
  • Minnesota
    • Minneapolis, Minnesota, United States, 55416
      • Novo Nordisk Investigational Site
  • Missouri
    • Chesterfield, Missouri, United States, 63017
      • Novo Nordisk Investigational Site
    • Springfield, Missouri, United States, 65807
      • Novo Nordisk Investigational Site
    • St. Charles, Missouri, United States, 63303
      • Novo Nordisk Investigational Site
    • St. Louis, Missouri, United States, 63110-1020
      • Novo Nordisk Investigational Site
    • St. Peters, Missouri, United States, 63376
      • Novo Nordisk Investigational Site
  • Montana
    • Billings, Montana, United States, 59101
      • Novo Nordisk Investigational Site
    • Butte, Montana, United States, 59701
      • Novo Nordisk Investigational Site
  • New Jersey
    • Lawrenceville, New Jersey, United States, 08648
      • Novo Nordisk Investigational Site
  • New York
    • Albany, New York, United States, 12206
      • Novo Nordisk Investigational Site
    • Mineola, New York, United States, 11501
      • Novo Nordisk Investigational Site
    • New York, New York, United States, 10029
      • Novo Nordisk Investigational Site
    • New York, New York, United States, 10032
      • Novo Nordisk Investigational Site
    • Staten Island, New York, United States, 10301
      • Novo Nordisk Investigational Site
    • Syracuse, New York, United States, 13210
      • Novo Nordisk Investigational Site
  • North Carolina
    • Greensboro, North Carolina, United States, 27408
      • Novo Nordisk Investigational Site
    • Morehead City, North Carolina, United States, 28557
      • Novo Nordisk Investigational Site
  • Ohio
    • Mentor, Ohio, United States, 44060
      • Novo Nordisk Investigational Site
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15224-2215
      • Novo Nordisk Investigational Site
    • Upper Darby, Pennsylvania, United States, 19082
      • Novo Nordisk Investigational Site
  • South Carolina
    • Greer, South Carolina, United States, 29651
      • Novo Nordisk Investigational Site
    • Myrtle Beach, South Carolina, United States, 29572
      • Novo Nordisk Investigational Site
    • Summerville, South Carolina, United States, 29485
      • Novo Nordisk Investigational Site
  • Tennessee
    • Chattanooga, Tennessee, United States, 37411
      • Novo Nordisk Investigational Site
    • Chattanooga, Tennessee, United States, 37404-1192
      • Novo Nordisk Investigational Site
    • Memphis, Tennessee, United States, 38119-3821
      • Novo Nordisk Investigational Site
    • Nashville, Tennessee, United States, 37212
      • Novo Nordisk Investigational Site
    • Nashville, Tennessee, United States, 37203
      • Novo Nordisk Investigational Site
  • Texas
    • Amarillo, Texas, United States, 79106
      • Novo Nordisk Investigational Site
    • Dallas, Texas, United States, 75230
      • Novo Nordisk Investigational Site
    • Dallas, Texas, United States, 75231
      • Novo Nordisk Investigational Site
    • Dallas, Texas, United States, 75246
      • Novo Nordisk Investigational Site
    • El Paso, Texas, United States, 79912
      • Novo Nordisk Investigational Site
    • Round Rock, Texas, United States, 78681
      • Novo Nordisk Investigational Site
    • Sugar Land, Texas, United States, 77478
      • Novo Nordisk Investigational Site
  • Utah
    • Salt Lake City, Utah, United States, 84102
      • Novo Nordisk Investigational Site
  • Vermont
    • Bennington, Vermont, United States, 05201
      • Novo Nordisk Investigational Site
  • Virginia
    • Norfolk, Virginia, United States, 23510
      • Novo Nordisk Investigational Site
  • Washington
    • Federal Way, Washington, United States, 98003
      • Novo Nordisk Investigational Site
    • Spokane, Washington, United States, 99208
      • Novo Nordisk Investigational Site
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53209
      • Novo Nordisk Investigational Site
    • Milwaukee, Wisconsin, United States, 53226
      • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• - Informed consent obtained
• - Type 1 diabetes mellitus for 12 months or longer
• - Basal bolus or CSII (Continuous Subcutaneous Insulin Infusion, insulin pump) treatment for 6 months or longer
• - Stable insulin treatment for the last 3 months prior to Screening, as judged and documented by the investigator
• - HbA1c 7.0-10% (Diabetes Control and Complications Trial (DCCT)), both inclusive, (corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC))
• - Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, complete trial related questionnaires, diaries, self-monitoring of plasma glucose, self titration of insulin and attend all scheduled visits

Exclusion Criteria:

• - Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPP-4) inhibitors
• - Use of any medication, which in the investigator's opinion could interfere with the glycaemic control or affect the subject's safety.Premix insulin is not allowed
• - Known proliferative retinopathy or maculopathy requiring acute treatment
• - Severe neuropathy, in particular autonomic neuropathy, i.e. gastroparesis, as judged by the investigator
• - Uncontrolled/ untreated blood pressure at screening above 160 mmHg for systolic or above 100 mmHg for diastolic
• - History of acute or chronic pancreatitis
• - Screening calcitonin value equal to or above 50 ng/L
• - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2)
• - Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Liraglutide 1.8 mg + insulin	Drug: liraglutide; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Experimental: Liraglutide 1.2 mg + insulin	Drug: liraglutide; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Experimental: Liraglutide 0.6 mg + insulin	Drug: liraglutide; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Placebo Comparator: Liraglutide placebo 0.6 mg + insulin	Drug: placebo; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Placebo Comparator: Liraglutide placebo 1.2 mg + insulin	Drug: placebo; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Placebo Comparator: Liraglutide placebo 1.8 mg + insulin	Drug: placebo; Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in HbA1c (Glycosylated Haemoglobin)	Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).	Week 0, week 52
Change From Baseline in Body Weight	Change from baseline in body weight at week 52. Missing values were handled by using a MMRM.	Week 0, week 52
Change From Baseline in Total Daily Insulin Dose	Change from baseline in total daily insulin dose at week 52. Change from baseline was represented in terms of ratio to baseline for insulin dose i.e. Total daily insulin dose at week 52/total daily insulin dose at baseline. Missing values were handled by using a MMRM.	Week 0, week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes	This is a confirmatory secondary endpoint. Symptomatic hypoglycaemic episodes were defined as: 1) Severe according to the American Diabetes Association (ADA) classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. OR 2) Self-monitoring of plasma glucose value of <3.1 mmol/L, with symptoms consistent with hypoglycaemia. A treatment emergent episode is defined as an episode with onset date (or increase in severity) on or after first day of exposure to randomised treatment and up to last dose + 7 days.	Weeks 0-52

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Publications and helpful links

General Publications

• Dejgaard TF, von Scholten BJ, Christiansen E, Kreiner FF, Bardtrum L, von Herrath M, Mathieu C, Madsbad S; ADJUNCT ONE and ADJUNCT TWO Investigators. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab. 2021 Dec;23(12):2752-2762. doi: 10.1111/dom.14532. Epub 2021 Sep 28. Erratum In: Diabetes Obes Metab. 2022 Nov;24(11):2280.
• Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B; ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016 Oct;39(10):1702-10. doi: 10.2337/dc16-0691. Epub 2016 Aug 9.

Helpful Links

• Clinical Trials at Novo Nordisk

Study record dates

Study Major Dates

• Study Start: November 1, 2013
• Primary Completion (Actual): June 1, 2015
• Study Completion (Actual): June 1, 2015

Study Registration Dates

• First Submitted: April 17, 2013
• First Submitted That Met QC Criteria: April 17, 2013
• First Posted (Estimate): April 22, 2013

Study Record Updates

• Last Update Posted (Actual): March 6, 2017
• Last Update Submitted That Met QC Criteria: January 16, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Hypoglycemic Agents; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; Liraglutide
• Other Study ID Numbers: NN9211-3919; 2012-003580-21 (EudraCT Number); U1111-1133-0590 (Other Identifier: WHO)